The Study
Creatine uptake promotes dendritic cell activation and enhances antitumor immunity
This study shows that in mice and human cells in a lab, creatine helps immune cells work better and fight tumors. But it doesn't prove that taking creatine pills will help people with cancer — we don't know yet if it works the same way in real patients.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
Your immune system has special cells called dendritic cells that teach T cells to attack cancer. These cells need lots of energy. Creatine, a supplement athletes use, helps these cells store more energy so they work better.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 548 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this suggests taking creatine might help cancer immunotherapy work better by making immune cells stronger, without new drugs.
- 2Creatine made dendritic cells produce more energy (ATP), activate more strongly, and better teach T cells to kill tumor cells.
- 3In mice, tumors grew slower.
- 4In human cells, dendritic cells also became more active.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
iScience
Year
2026
Authors
Elliot Kang, James Elsten-Brown, Yu-Chen Wang, A. Lam, E. Sanchez, R. Wen, Tiffany Wang, Jennifer Chiang, Quentin Scarborough, Yan-Ruide Li, Yichen Zhu, Jie Huang, Matthew Williams, Sarah L Eckl, Bo Li, Lili Yang
Related Content
Claims (10)
Creatine makes dendritic cells more effective at triggering immune responses against cancer. This leads to stronger anti-tumor immune attacks and causes tumors to shrink.
Creatine supplementation increases the ability of human dendritic cells derived from monocytes to activate T cells that recognize tumor antigens in laboratory cell cultures.
Creatine entering dendritic cells via the Slc6a8 transporter increases their energy storage, which raises levels of activation markers and inflammatory signals and improves their ability to activate CD8+ T cells in both mice and humans.
In mice with melanoma, creatine supplementation increases the number and activity of type 1 dendritic cells in tumors and decreases tumor size.
When dendritic cells take up creatine, their intracellular ATP levels are maintained, and their Toll-like receptor signaling through the NF-κB p65 pathway is increased, leading to activation and cytokine production when exposed to inflammatory stimuli.
In mice with cancer, giving them creatine at doses similar to what humans take causes more cancer spread (metastasis) and shorter survival times.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.